vs
安进（AMGN）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是NEUROCRINE BIOSCIENCES INC的12.2倍（$9.9B vs $805.5M）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs 13.5%，领先5.6%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs 8.6%）。安进自由现金流更多（$961.0M vs $386.0M）。过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs 15.1%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
AMGN vs NBIX — 直观对比
营收规模更大
AMGN
是对方的12.2倍
$805.5M
营收增速更快
NBIX
高出19.7%
8.6%
净利率更高
NBIX
高出5.6%
13.5%
自由现金流更多
AMGN
多$575.0M
$386.0M
两年增速更快
NBIX
近两年复合增速
15.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $805.5M |
| 净利润 | $1.3B | $153.7M |
| 毛利率 | 69.8% | 97.8% |
| 营业利润率 | 27.6% | 26.2% |
| 净利率 | 13.5% | 19.1% |
| 营收同比 | 8.6% | 28.3% |
| 净利润同比 | 112.6% | 49.1% |
| 每股收益（稀释后） | $2.45 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNNBIX
| Q4 25 | $9.9B | $805.5M | ||
| Q3 25 | $9.6B | $794.9M | ||
| Q2 25 | $9.2B | $687.5M | ||
| Q1 25 | $8.1B | $572.6M | ||
| Q4 24 | $9.1B | $627.7M | ||
| Q3 24 | $8.5B | $622.1M | ||
| Q2 24 | $8.4B | $590.2M | ||
| Q1 24 | $7.4B | $515.3M |
净利润AMGNNBIX
| Q4 25 | $1.3B | $153.7M | ||
| Q3 25 | $3.2B | $209.5M | ||
| Q2 25 | $1.4B | $107.5M | ||
| Q1 25 | $1.7B | $7.9M | ||
| Q4 24 | $627.0M | $103.1M | ||
| Q3 24 | $2.8B | $129.8M | ||
| Q2 24 | $746.0M | $65.0M | ||
| Q1 24 | $-113.0M | $43.4M |
毛利率AMGNNBIX
| Q4 25 | 69.8% | 97.8% | ||
| Q3 25 | 67.8% | 98.2% | ||
| Q2 25 | 67.2% | 98.4% | ||
| Q1 25 | 63.6% | 98.4% | ||
| Q4 24 | 65.7% | 98.5% | ||
| Q3 24 | 61.1% | 98.7% | ||
| Q2 24 | 61.4% | 98.4% | ||
| Q1 24 | 57.0% | 98.5% |
营业利润率AMGNNBIX
| Q4 25 | 27.6% | 26.2% | ||
| Q3 25 | 26.4% | 30.1% | ||
| Q2 25 | 28.9% | 21.2% | ||
| Q1 25 | 14.5% | 4.1% | ||
| Q4 24 | 25.4% | 22.6% | ||
| Q3 24 | 24.1% | 29.5% | ||
| Q2 24 | 22.8% | 24.6% | ||
| Q1 24 | 13.3% | 19.3% |
净利率AMGNNBIX
| Q4 25 | 13.5% | 19.1% | ||
| Q3 25 | 33.7% | 26.4% | ||
| Q2 25 | 15.6% | 15.6% | ||
| Q1 25 | 21.2% | 1.4% | ||
| Q4 24 | 6.9% | 16.4% | ||
| Q3 24 | 33.3% | 20.9% | ||
| Q2 24 | 8.9% | 11.0% | ||
| Q1 24 | -1.5% | 8.4% |
每股收益（稀释后）AMGNNBIX
| Q4 25 | $2.45 | $1.49 | ||
| Q3 25 | $5.93 | $2.04 | ||
| Q2 25 | $2.65 | $1.06 | ||
| Q1 25 | $3.20 | $0.08 | ||
| Q4 24 | $1.17 | $1.00 | ||
| Q3 24 | $5.22 | $1.24 | ||
| Q2 24 | $1.38 | $0.63 | ||
| Q1 24 | $-0.21 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $713.0M |
| 总债务越低越好 | $54.6B | — |
| 股东权益账面价值 | $8.7B | $3.3B |
| 总资产 | $90.6B | $4.6B |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNNBIX
| Q4 25 | $9.1B | $713.0M | ||
| Q3 25 | $9.4B | $340.2M | ||
| Q2 25 | $8.0B | $264.0M | ||
| Q1 25 | $8.8B | $194.1M | ||
| Q4 24 | $12.0B | $233.0M | ||
| Q3 24 | $9.0B | $349.1M | ||
| Q2 24 | $9.3B | $139.7M | ||
| Q1 24 | $9.7B | $396.3M |
总债务AMGNNBIX
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNNBIX
| Q4 25 | $8.7B | $3.3B | ||
| Q3 25 | $9.6B | $3.0B | ||
| Q2 25 | $7.4B | $2.7B | ||
| Q1 25 | $6.2B | $2.5B | ||
| Q4 24 | $5.9B | $2.6B | ||
| Q3 24 | $7.5B | $2.7B | ||
| Q2 24 | $5.9B | $2.5B | ||
| Q1 24 | $5.0B | $2.4B |
总资产AMGNNBIX
| Q4 25 | $90.6B | $4.6B | ||
| Q3 25 | $90.1B | $4.3B | ||
| Q2 25 | $87.9B | $3.9B | ||
| Q1 25 | $89.4B | $3.7B | ||
| Q4 24 | $91.8B | $3.7B | ||
| Q3 24 | $90.9B | $3.5B | ||
| Q2 24 | $90.9B | $3.3B | ||
| Q1 24 | $93.0B | $3.5B |
负债/权益比AMGNNBIX
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $386.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 47.9% |
| 资本支出强度资本支出/营收 | 6.5% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.20× | 2.53× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $743.9M |
8季度趋势，按日历期对齐
经营现金流AMGNNBIX
| Q4 25 | $1.6B | $388.4M | ||
| Q3 25 | $4.7B | $227.5M | ||
| Q2 25 | $2.3B | $102.0M | ||
| Q1 25 | $1.4B | $64.8M | ||
| Q4 24 | $4.8B | $242.5M | ||
| Q3 24 | $3.6B | $158.0M | ||
| Q2 24 | $2.5B | $64.6M | ||
| Q1 24 | $689.0M | $130.3M |
自由现金流AMGNNBIX
| Q4 25 | $961.0M | $386.0M | ||
| Q3 25 | $4.2B | $214.3M | ||
| Q2 25 | $1.9B | $89.5M | ||
| Q1 25 | $980.0M | $54.1M | ||
| Q4 24 | $4.4B | $235.2M | ||
| Q3 24 | $3.3B | $149.9M | ||
| Q2 24 | $2.2B | $53.0M | ||
| Q1 24 | $459.0M | $119.1M |
自由现金流率AMGNNBIX
| Q4 25 | 9.7% | 47.9% | ||
| Q3 25 | 44.4% | 27.0% | ||
| Q2 25 | 20.8% | 13.0% | ||
| Q1 25 | 12.0% | 9.4% | ||
| Q4 24 | 48.4% | 37.5% | ||
| Q3 24 | 39.0% | 24.1% | ||
| Q2 24 | 26.5% | 9.0% | ||
| Q1 24 | 6.2% | 23.1% |
资本支出强度AMGNNBIX
| Q4 25 | 6.5% | 0.3% | ||
| Q3 25 | 4.6% | 1.7% | ||
| Q2 25 | 4.0% | 1.8% | ||
| Q1 25 | 5.0% | 1.9% | ||
| Q4 24 | 4.1% | 1.2% | ||
| Q3 24 | 3.0% | 1.3% | ||
| Q2 24 | 2.8% | 2.0% | ||
| Q1 24 | 3.1% | 2.2% |
现金转化率AMGNNBIX
| Q4 25 | 1.20× | 2.53× | ||
| Q3 25 | 1.46× | 1.09× | ||
| Q2 25 | 1.59× | 0.95× | ||
| Q1 25 | 0.80× | 8.20× | ||
| Q4 24 | 7.61× | 2.35× | ||
| Q3 24 | 1.26× | 1.22× | ||
| Q2 24 | 3.30× | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
